TRYPTYR Sales Forecast, and Market Size Analysis - 2034
상품코드:1909227
리서치사:DelveInsight
발행일:On Demand Report
페이지 정보:영문 30 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
트립티어(TRYPTYR)의 성장 촉진요인
1. 시장 점유율 확대와 신규 환자 수 증가
트립티어(TM, 아코르트레몬)은 미충족 수요가 높은 대규모 성장 시장인 안구건조증 질환(DED) 치료를 위해 개발 중인 연구용 국소 안과 치료제입니다.
아직 시판화되어 있지는 않지만, 강력한 후기 임상시험 데이터에 의해 안과의사들 사이에 큰 기대가 전해지고 있어, 승인 후에는 신규 환자수가 급속히 증가할 전망입니다.
Alcon의 안과 치료 부문에서의 깊은 상업적 입지, 강력한 의사 관계 및 교육 이니셔티브는 출시 후 빠른 시장 점유율 확보를 지원할 것으로 예상되며, 특히 기존 치료법으로 적절히 관리되지 않는 환자들 사이에서 그러할 것입니다.
2. 주요 적응증의 확대
안구건조증질환(주요적응증) : 트립티어(TRYPTYR)는 안구건조증질환의 징후 및 증상의 치료를 목적으로 개발되어 있으며, 임상시험은 신속하고 임상적으로 유의한 증상완화를 입증하고 있습니다.
광범위한 안구건조증 환자 스펙트럼 : 새로운 작용 기전은 증발성 및 복합성 안구건조증을 포함한 다양한 안구건조증 환자군에 대한 잠재적 사용을 지원합니다.
초기 치료 옵션 가능성 : 증상 개선의 빠른 발현으로 만성 항염증 치료제 대비 치료 알고리즘 상 더 이른 단계에서의 사용이 가능할 수 있습니다.
수명 주기의 기회 : 안구건조증의 성공은 관련 안 표면 질환으로의 향후 전개를 가능하게 할 수 있습니다.
3. 지리적 확대
세계의 개발 전략 : Alcon은 광범위한 세계 규제 전략을 추진하고 있으며, 처음에는 미국 및 기타 주요 안과 시장에 중점을 둡니다.
아시아태평양의 성장 가능성 : 안구건조증의 높은 유병률, 스크린 노출 시간 증가, 노화, 안과 의료에 대한 접근성 개선으로 아시아태평양은 장기 성장의 중요한 지역으로 자리매김하고 있습니다.
확립된 상업 인프라 : Alcon의 기존 세계 유통망 및 안과 부문에 특화된 판매 네트워크는 승인 후 지역 확대를 가속화할 것으로 예측됩니다.
4. 신규 적응증 승인
안구건조증에 대한 규제 신청 과정 : 트립티어(TRYPTYR)는 3상 시험의 양호한 결과에 근거하여 안구건조증에 대한 규제 당국에의 신청을 향해 진행하고 있습니다.
최초의 치료제 가능성 : 승인은 안구건조증 질환에 새로운 치료군을 도입하여 전반적인 치료 환경을 확대할 것입니다.
포트폴리오 다양화 : 트립티어(TRYPTYR)는 Alcon의 의약품 포트폴리오를 크게 강화하여 수술 및 시력 관리 제품에서 회사의 이점을 보완합니다.
5. 안구건조증 치료 수요 증가 경향
확대를 계속하는 대규모 시장 : 고령화, 디지털 안정 피로, 환경 요인으로 인해 안구건조증의 유병률은 세계적으로 증가하고 있습니다.
높은 치료 불만족도 : 많은 환자들이 기존 치료에도 불구하고 증상이 지속되어 혁신적인 치료 옵션에 대한 수요가 높습니다.
예상되는 빠른 시장 수용 : 임상적으로 의미 있는 증상 완화와 우수한 내약성이 출시 후 강력한 처방량을 이끌 것으로 기대됩니다.
6. 경쟁 우위와 시장 동향
신규 TRPM8 작용제 기작 : 트립티어(TRYPTYR)는 각막의 냉감 수용체인 TRPM8 수용체를 활성화시켜 자연적인 눈물 생성을 촉진합니다. 이것은 안구건조증(DED)에 대 한 신경 감각 기반의 차별화 된 접근을 제공 합니다.
신속한 증상 완화 : 항염증제 대비 빠른 작용 발현으로 환자 만족도와 치료 순응도 향상 가능 합니다.
시장 동향 및의 무결성 : 작용기전에 기초한 치료법과 환자 보고 결과에 대한 중시가 높아지는 가운데, 트립티어(TRYPTYR)의 위치 지정은 지지됩니다.
실제 임상 증거(RWE)의 미래 역할 : 승인 후 실제 임상 데이터는 지불자 측의 신뢰 획득 및 장기적인 지침에 통합하는 데 중요합니다.
이 보고서는 주요 7개국(미국, EU4(독일, 프랑스, 이탈리아, 스페인), 영국)에서 안구건조증 등의 승인된 적응증에 대한 트립티어(TRYPTYR)의 종합적인 인사이트를 제공합니다. 이 보고서는 2020년부터 2034년까지 7개국의 주요 트립티어(TRYPTYR) 사용 현황, 진입 전망, 승인된 적응증의 업적에 대한 상세한 분석, 승인된 적응증에서 트립티어(TRYPTYR)의 상세한 설명을 제공합니다. 또한 이 제품의 매출 예측, 작용기전(MoA), 투여량 및 투여 방법, 규제상의 이정표를 포함한 연구개발 및 기타 개발 활동에 대한 통찰을 제공합니다. 또한 과거 및 현재 트립티어(TRYPTYR) 실적, 미래 시장 평가, 주요 7개국 시장 예측 분석, SWOT 분석, 분석가 견해, 경쟁업체의 종합적인 개요, 각 적응증에 대한 기타 신흥 치료법의 개요, 트립티어(TRYPTYR) 매출 예측 분석, 시장 주도 요인 등도 정리했습니다.
목차
제1장 보고서 개요
제2장 안구건조증 등의 승인된 적응증에 대한 트립티어(TRYPTYR) 개요
제품 상세
임상 개발
임상 연구
임상시험 정보
안전성과 유효성
기타 개발 활동
제품 프로파일
제3장 트립티어(TRYPTYR) : 경쟁 구도(시판 중인 치료제)
제4장 트립티어(TRYPTYR) : 경쟁 구도(개발 후기 치료제)
제5장 트립티어(TRYPTYR) : 시장 평가
승인된 적응증에 대한 시장 전망
주요 7개국 분석
승인된 적응증에 대한 주요 7개국 시장 규모
국가별 시장 분석
미국
독일
영국
제6장 트립티어(TRYPTYR) : SWOT 분석
제7장 애널리스트의 견해
제8장 부록
제9장 DelveInsight의 서비스 내용
제10장 면책사항
제11장 DelveInsight 정보
제12장 보고서 구매 옵션
HBR
영문 목차
영문목차
Key Factors Driving TRYPTYR Growth
1. Market Share Gains and New Patient Starts
TRYPTYR(TM) (Acoltremon) is an investigational topical ophthalmic therapy being developed for dry eye disease (DED), a large and growing market with high unmet need.
Although not yet commercialized, strong late-stage clinical data have generated significant anticipation among ophthalmologists, positioning TRYPTYR for rapid new patient starts upon approval.
Alcon's deep commercial footprint in eye care, coupled with strong physician relationships and education initiatives, is expected to support fast uptake post-launch, particularly among patients inadequately managed with existing therapies.
2. Expansion Across Key Indications
Dry Eye Disease (Primary Indication): TRYPTYR is being developed for the treatment of signs and symptoms of DED, with clinical studies demonstrating rapid and clinically meaningful symptom relief.
Broad DED Patient Spectrum: The novel mechanism supports potential use across a wide range of dry eye patients, including those with evaporative and mixed-etiology disease.
Earlier-Line Therapy Potential: Fast onset of symptom improvement may enable use earlier in the treatment algorithm compared with chronic anti-inflammatory therapies.
Lifecycle Opportunities: Success in DED may enable future exploration in related ocular surface disorders.
3. Geographic Expansion
Global Development Strategy: Alcon is pursuing a broad global regulatory strategy, with initial focus on the U.S. and other major ophthalmology markets.
Asia-Pacific Growth Potential: High DED prevalence, increasing screen exposure, aging populations, and improving access to eye care position Asia-Pacific as a key long-term growth region.
Established Commercial Infrastructure: Alcon's existing global distribution and ophthalmology-focused sales network is expected to accelerate geographic expansion following approval.
4. New Indication Approvals
Regulatory Pathway for DED: TRYPTYR is progressing toward regulatory submissions for dry eye disease based on positive Phase III data.
First-in-Class Potential: Approval would introduce a new therapeutic class in DED, broadening the overall treatment landscape.
Portfolio Diversification: TRYPTYR would significantly strengthen Alcon's pharmaceutical portfolio, complementing its dominant position in surgical and vision care products.
5. Strong Dry Eye Volume Momentum
Large and Growing Market: Dry eye disease prevalence continues to rise globally due to aging populations, digital eye strain, and environmental factors.
High Treatment Dissatisfaction: Many patients remain symptomatic despite current therapies, supporting strong demand for innovative options.
Expected Rapid Uptake: Clinically meaningful symptom relief and favorable tolerability are expected to drive strong prescription volumes post-launch.
6. Competitive Differentiation and Market Trends
Novel TRPM8 Agonist Mechanism: TRYPTYR activates corneal cold-sensing TRPM8 receptors, stimulating natural tear production and offering a differentiated, neurosensory-based approach to DED.
Rapid Symptom Relief: Faster onset compared with anti-inflammatory agents may improve patient satisfaction and adherence.
Alignment with Market Trends: Growing emphasis on mechanism-driven therapies and patient-reported outcomes supports TRYPTYR's positioning.
Future Role of Real-World Evidence (RWE): Post-approval RWE will be important for payer confidence and long-term guideline inclusion.
TRYPTYR Recent Developments
Alcon announced positive Phase III clinical trial results for TRYPTYR(TM) (acoltremon) demonstrating statistically significant improvement in dry eye symptoms, including rapid onset of action, compared with vehicle. These results marked a major milestone and positioned TRYPTYR as a potential first-in-class neurosensory therapy for dry eye disease. Alcon has highlighted TRYPTYR as a key near-term growth driver within its pharmaceutical pipeline and has communicated plans to advance toward regulatory submissions, reinforcing its strategic focus on expanding beyond devices into innovative ocular surface therapies.
"TRYPTYR Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of TRYPTYR for approved indication like Dry eyes in the 7MM. A detailed picture of TRYPTYR's existing usage in anticipated entry and performance in approved indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the TRYPTYR for approved indications. The TRYPTYR market report provides insights about TRYPTYR's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current TRYPTYR performance, future market assessments inclusive of the TRYPTYR market forecast analysis for approved indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of TRYPTYR sales forecasts, along with factors driving its market.
TRYPTYR Drug Summary
TRYPTYR is an ophthalmic solution containing Acoltremon 0.003%, developed by Alcon and FDA-approved in May 2025 for treating the signs and symptoms of dry eye disease. As a first-in-class agonist of transient receptor potential melastatin 8 (TRPM8) thermoreceptors on corneal sensory nerves, it activates trigeminal nerve signaling to rapidly stimulate natural basal tear production, addressing tear deficiency without preservatives. Administered as one drop per eye twice daily (about 12 hours apart) using single-dose vials, it demonstrated significant improvements in Schirmer tear test scores (>=10 mm increase in 42.6-53.2% of patients by day 14 versus vehicle), with common side effects including instillation site pain or burning. The report provides TRYPTYR's sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the TRYPTYR Market Report
The report provides insights into:
A comprehensive product overview including the TRYPTYR MoA, description, dosage and administration, research and development activities in approved indication like Dry eyes.
Elaborated details on TRYPTYR regulatory milestones and other development activities have been provided in TRYPTYR market report.
The report also highlights TRYPTYR's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved indications across the United States, Europe, and Japan.
The TRYPTYR market report also covers the patents information, generic entry and impact on cost cut.
The TRYPTYR market report contains current and forecasted TRYPTYR sales for approved indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The TRYPTYR market report also features the SWOT analysis with analyst views for TRYPTYR in approved indications.
Methodology:
The TRYPTYR market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
TRYPTYR Analytical Perspective by DelveInsight
In-depth TRYPTYR Market Assessment
This TRYPTYR sales market forecast report provides a detailed market assessment of TRYPTYR for approved indication like Dry eyes in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted TRYPTYR sales data uptil 2034.
TRYPTYR Clinical Assessment
The TRYPTYR market report provides the clinical trials information of TRYPTYR for approved indications covering trial interventions, trial conditions, trial status, start and completion dates.
TRYPTYR Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
TRYPTYR Market Potential & Revenue Forecast
Projected market size for the TRYPTYR and its key indications
Commercial partnerships, licensing deals, and M&A activity
TRYPTYR Clinical Differentiation
TRYPTYR Efficacy & safety advantages over existing drugs
TRYPTYR Unique selling points
TRYPTYR Market Report Highlights
In the coming years, the TRYPTYR market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The TRYPTYR companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TRYPTYR's dominance.
Other emerging products for Dry eyes are expected to give tough market competition to TRYPTYR and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TRYPTYR in approved indications.
Analyse TRYPTYR cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted TRYPTYR sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of TRYPTYR in approved indications.
Key Questions:
What is the class of therapy, route of administration and mechanism of action of TRYPTYR? How strong is TRYPTYR's clinical and commercial performance?
What is TRYPTYR's clinical trial status in each individual indications such as Dry eyes and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TRYPTYR Manufacturers?
What are the key designations that have been granted to TRYPTYR for approved indications? How are they going to impact TRYPTYR's penetration in various geographies?
What is the current and forecasted TRYPTYR market scenario for approved indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of TRYPTYR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to TRYPTYR for approved indications?
Which are the late-stage emerging therapies under development for the treatment of approved indications?
How cost-effective is TRYPTYR? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
1. Report Introduction
2. TRYPTYR Overview in approved indications like Dry eyes
